Research progress on intranasal treatment for Parkinson's disease
Authors:
Open Access
- 21 April 2024
- journal article
- review article
- Published by Wiley in Neuroprotection
- Vol. 2 (2) , 79-99
Abstract
Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder globally, significantly affecting the quality of life of affected individuals. Systemic drug delivery to the brain is inefficient because of first‐pass metabolism, the blood‐brain barrier (BBB), and the blood‐cerebrospinal fluid barrier. This inefficiency necessitates increased dosage as the disease progresses, leading to severe side effects that compromise the efficacy of the medication. Nose‐to‐brain (N2B) administration bypasses the BBB, allowing delivery of both small molecules and large protein substances to the central nervous system. Compared with systemic administration, this method enhances brain bioavailability, reduces enzymatic degradation, and minimizes systemic adverse reactions. However, the N2B delivery system is associated with several critical challenges, including mucociliary clearance, enzymatic degradation, and drug translocation via efflux mechanisms. This paper provides a comprehensive overview of the current research progress in intranasal treatment of PD, considering both preclinical and clinical studies, and discusses the physiological aspects and limitations of its delivery system.Keywords
This publication has 253 references indexed in Scilit:
- Intermittent Apomorphine Use for off Period Rescue in Parkinson's Disease: A Pragmatic Review of over Three Decades of Clinical ExperienceMovement Disorders Clinical Practice, 2022
- DoE‐based validation of a HPLC–UV method for quantification of rotigotine nanocrystals: Application to in vitro dissolution and ex vivo nasal permeation studiesElectrophoresis, 2021
- Stem cell‐based therapy for Parkinson’s disease with a focus on human endometrium‐derived mesenchymal stem cellsJournal of Cellular Physiology, 2018
- A randomized, double‐blind phase I/IIa study of intranasal glutathione in Parkinson's diseaseMovement Disorders, 2015
- Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive ImpairmentArchives of Neurology, 2012
- Achyranthes bidentata polypeptides confer neuroprotection through inhibition of reactive oxygen species production, Bax expression, and mitochondrial dysfunction induced by overstimulation of N‐methyl‐D‐aspartate receptorsJournal of Neuroscience Research, 2009
- Randomized, double‐blind, pilot evaluation of intravenous glutathione in Parkinson's diseaseMovement Disorders, 2009
- Glial reactions in Parkinson's diseaseMovement Disorders, 2007
- Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson diseaseAnnals of Neurology, 2006
- Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal gangliaAnnals of Neurology, 1994